ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 1103-1104

  Dougados, Maxime ^a   Braun, Jurgen ^b   Vargas, Rubén Burgos ^c   Gossec, Laure ^a   Maksymowych, Walter ^d   Sieper, Joachim ^e   Van Der Heijde, Désirée ^f  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d UNIVERSITY OF ALBERTA   (Canada)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DACTYLITIS; DATA COLLECTION METHOD; DRUG USE; ENTERITIS; ENTHESITIS; EPIDEMIOLOGY; HUMAN; LETTER; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; SPONDYLARTHRITIS; SYNOVITIS; UVEITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DATA COLLECTION; HUMANS; PRACTICE GUIDELINES AS TOPIC; SPONDYLARTHRITIS;

EID: 84860915503     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201038     Document Type: Letter

References (10)

1. Assessment of SpondyloArthritis International Society (ASAS). http://www.asas-group.org (accessed 16 Jan 2012).
2. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86. (Pubitemid 32758236)
3. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25-31.
4. van der Heijde D, Dougados M, Davis J, et al.; ASsessment in Ankylosing Spondylitis International Working Group. ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005;52:386-94. (Pubitemid 40216302)
5. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68 (Suppl 2):ii1-44.
6. Dougados M, Simon P, Braun J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011;70:249-51.
7. Dougados M, Braun J, Szanto S, et al. NSAID-intake according to the ASAS score in clinical trials evaluating TNF blockers: the example of etanercept in advanced ankylosing spondylitis. Arthritis Care Res 2011 Oct 17 [Epub ahead of print].
8. Poddubnyy D, Haibel H, Listing J, et al. Influence of NSAIDs intake on the radiographic spinal progression over two years in patients with early axial spondyloarthritis. Ann Rheum Dis 2011;70(Suppl 3):128.
9. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. (Pubitemid 41117431)
10. Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010;69:226-9.